Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 28, 2016, Pages 7852-7857

  Priyamvada, Lalita ^a   Quicke, Kendra M ^a   Hudson, William H ^a   Onlamoon, Nattawat ^b   Sewatanon, Jaturong ^a,b   Edupuganti, Srilatha ^a   Pattanapanyasat, Kovit ^b   Chokephaibulkit, Kulkanya ^b   Mulligan, Mark J ^a   Wilson, Patrick C ^c   Ahmed, Rafi ^a   Suthar, Mehul S ^a   Wrammert, Jens ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antibodies; B cell responses; Cross reactivity; Zika virus

Indexed keywords

FC RECEPTOR; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ARTICLE; CELL LYSATE; CLINICAL ARTICLE; CONVALESCENCE; CROSS REACTION; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; MONOCYTE; NONHUMAN; PLASMABLAST; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS; THAI (CITIZEN); VIRUS NEUTRALIZATION; WESTERN BLOTTING; ZIKA FEVER; ZIKA VIRUS; ANIMAL; ANTIBODY PRODUCTION; CHEMISTRY; CHLOROCEBUS AETHIOPS; DENGUE VIRUS; IMMUNOLOGY; VERO CELL LINE; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; CERCOPITHECUS AETHIOPS; CROSS REACTIONS; DENGUE; DENGUE VIRUS; HUMANS; MONOCYTES; NEUTRALIZATION TESTS; VERO CELLS; VIRAL ENVELOPE PROTEINS; ZIKA VIRUS;

EID: 84978153824     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1607931113     Document Type: Article

References (40)

1. Dick GW, Kitchen SF, Haddow AJ (1952) Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 46(5):509-520.
2. Duffy MR, et al. (2009) Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 360(24):2536-2543.
3. Ioos S, et al. (2014) Current Zika virus epidemiology and recent epidemics. Med Mal Infect 44(7):302-307.
4. Musso D, Gubler DJ (2016) Zika Virus. Clin Microbiol Rev 29(3):487-524.
5. Cao-Lormeau VM, et al. (2016) Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study. Lancet 387(10027):1531-1539.
6. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR (2016) Zika virus and birth defects-Reviewing the evidence for causality. N Engl J Med 374(20):1981-1987.
7. Mlakar J, et al. (2016) Zika virus associated with microcephaly. N Engl J Med 374(10):951-958.
8. Lanciotti RS, et al. (2008) Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 14(8):1232-1239.
9. Musso D, et al. (2015) Detection of Zika virus in saliva. J Clin Virol 68:53-55.
10. Fonseca K, et al. (2014) First case of Zika virus infection in a returning Canadian traveler. Am J Trop Med Hyg 91(5):1035-1038.
11. Bhatt S, et al. (2013) The global distribution and burden of dengue. Nature 496(7446):504-507.
12. Dasgupta S, et al.; Zika Virus Response Epidemiology and Laboratory Team; CDC; CDC (all these individuals meet collaborator criteria) (2016) Patterns in Zika virus testing and infection, by report of symptoms and pregnancy status - United States, January 3-March 5, 2016. MMWR Morb Mortal Wkly Rep 65(15):395-399.
13. Priyamvada L, et al. (2016) B cell responses during secondary dengue infection are dominated by highly cross-reactive, memory-derived plasmablasts. J Virol, JVI.03203-15.
14. Beltramello M, et al. (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8(3):271-283.
15. Xu M, et al. (2012) Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. J Immunol 189(12):5877-5885.
16. Sirohi D, et al. (2016) The 3.8 Å resolution cryo-EM structure of Zika virus. Science 352(6284):467-470.
17. Smith SA, et al. (2012) Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86(5):2665-2675.
18. Olagnier D, et al. (April 27, 2016) Dengue virus immunopathogenesis: Lessons applicable to the emergence of Zika virus. J Mol Biol, 10.1016/j.jmb.2016.04.024.
19. Wikan N, Suputtamongkol Y, Yoksan S, Smith DR, Auewarakul P (2016) Immunological evidence of Zika virus transmission in Thailand. Asian Pac J Trop Med 9(2):141-144.
20. Tappe D, et al. (2014) First case of laboratory-confirmed Zika virus infection imported into Europe, November 2013. Euro Surveill 19(4):20685.
21. Lai CY, et al. (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82(13):6631-6643.
22. Costin JM, et al. (2013) Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol 87(1):52-66.
23. Deng YQ, et al. (2011) A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One 6(1):e16059.
24. Vogt MR, et al. (2011) Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol 85(22):11567-11580.
25. Sultana H, et al. (2009) Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol 183(1):650-660.
26. Gallichotte EN, et al. (2015) A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. MBio 6(5):e01461-e15.
27. de Alwis R, et al. (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 109(19):7439-7444.
28. Dejnirattisai W, et al. (2015) A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16(2):170-177.
29. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS (1989) Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40(4):444-451.
30. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421-467.
31. Vaughn DW, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181(1):2-9.
32. Libraty DH, et al. (2002) Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185(9):1213-1221.
33. Yenchitsomanus PT, et al. (1996) Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR). Southeast Asian J Trop Med Public Health 27(2):228-236.
34. Zhang X, et al. (2013) Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nat Struct Mol Biol 20(1):105-110.
35. Durbin AP, et al. (2006) rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. Hum Vaccin 2(6):255-260.
36. Pettersen EF, et al. (2004) UCSF Chimera-A visualization system for exploratory research and analysis. J Comput Chem 25(13):1605-1612.
37. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100(12):6986-6991.
38. Butrapet S, et al. (2011) Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion. Virology 413(1):118-127.
39. Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427(6972):313-319.
40. Hsieh SC, Tsai WY, Wang WK (2010) The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum. J Virol 84(9):4782-4797.